148 related articles for article (PubMed ID: 25771366)
1. Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy.
Reynolds TS; Bandari RP; Jiang Z; Smith CJ
Curr Radiopharm; 2016; 9(1):33-43. PubMed ID: 25771366
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors.
Zhang H; Chen J; Waldherr C; Hinni K; Waser B; Reubi JC; Maecke HR
Cancer Res; 2004 Sep; 64(18):6707-15. PubMed ID: 15374988
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
[TBL] [Abstract][Full Text] [Related]
4. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
Lantry LE; Cappelletti E; Maddalena ME; Fox JS; Feng W; Chen J; Thomas R; Eaton SM; Bogdan NJ; Arunachalam T; Reubi JC; Raju N; Metcalfe EC; Lattuada L; Linder KE; Swenson RE; Tweedle MF; Nunn AD
J Nucl Med; 2006 Jul; 47(7):1144-52. PubMed ID: 16818949
[TBL] [Abstract][Full Text] [Related]
5. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
[TBL] [Abstract][Full Text] [Related]
6. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells.
Smith CJ; Gali H; Sieckman GL; Hayes DL; Owen NK; Mazuru DG; Volkert WA; Hoffman TJ
Nucl Med Biol; 2003 Feb; 30(2):101-9. PubMed ID: 12623108
[TBL] [Abstract][Full Text] [Related]
7. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.
Smith CJ; Sieckman GL; Owen NK; Hayes DL; Mazuru DG; Volkert WA; Hoffman TJ
Anticancer Res; 2003; 23(1A):63-70. PubMed ID: 12680195
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes.
Smith CJ; Volkert WA; Hoffman TJ
Nucl Med Biol; 2005 Oct; 32(7):733-40. PubMed ID: 16243649
[TBL] [Abstract][Full Text] [Related]
9. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
[TBL] [Abstract][Full Text] [Related]
11. In vitro binding evaluation of 177Lu-AMBA, a novel 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues.
Thomas R; Chen J; Roudier MM; Vessella RL; Lantry LE; Nunn AD
Clin Exp Metastasis; 2009; 26(2):105-19. PubMed ID: 18975117
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and exploration of novel radiolabeled bombesin peptides for targeting receptor positive tumor.
De K; Banerjee I; Sinha S; Ganguly S
Peptides; 2017 Mar; 89():17-34. PubMed ID: 28088445
[TBL] [Abstract][Full Text] [Related]
13. Investigation of bombesin peptide as a targeting ligand for the gastrin releasing peptide (GRP) receptor.
Begum AA; Moyle PM; Toth I
Bioorg Med Chem; 2016 Nov; 24(22):5834-5841. PubMed ID: 27670095
[TBL] [Abstract][Full Text] [Related]
14. Toward the Optimization of Bombesin-Based Radiotracers for Tumor Targeting.
Valverde IE; Vomstein S; Mindt TL
J Med Chem; 2016 Apr; 59(8):3867-77. PubMed ID: 27054526
[TBL] [Abstract][Full Text] [Related]
15. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates.
Ait-Mohand S; Fournier P; Dumulon-Perreault V; Kiefer GE; Jurek P; Ferreira CL; Bénard F; Guérin B
Bioconjug Chem; 2011 Aug; 22(8):1729-35. PubMed ID: 21761921
[TBL] [Abstract][Full Text] [Related]
17. Development of a new bombesin analog radiolabeled with lutetium-177: in vivo evaluation of the biological properties in Balb-C mice.
Pujatti PB; Santos JS; Massicano AV; Mengatti J; De Araújo EB
Cell Mol Biol (Noisy-le-grand); 2010 May; 56(2):18-24. PubMed ID: 20525454
[TBL] [Abstract][Full Text] [Related]
18. Lutetium-177-labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy.
Panigone S; Nunn AD
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):310-21. PubMed ID: 17043628
[TBL] [Abstract][Full Text] [Related]
19. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog.
Dijkgraaf I; Franssen GM; McBride WJ; D'Souza CA; Laverman P; Smith CJ; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2012 Jun; 53(6):947-52. PubMed ID: 22570329
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer.
Carlucci G; Ananias HJ; Yu Z; Hoving HD; Helfrich W; Dierckx RA; Liu S; de Jong IJ; Elsinga PH
Mol Pharm; 2013 May; 10(5):1716-24. PubMed ID: 23590837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
